Abstract
PTP-1B represents an attractive target for the treatment of type 2 diabetes and obesity. Given the role that protein phosphatases play in the regulation of many biologically relevant processes, inhibitors against PTP-1B must be not only potent, but also selective. It has been extremely difficult to synthesize inhibitors that are selective over the highly homologous TCPTP. We have successfully exploited the conservative Leu119 to Val substitution between the two enzymes to synthesize a PTP-1B inhibitor that is an order of magnitude more selective over TCPTP. Structural analyses of PTP-1B/inhibitor complexes show a conformation-assisted inhibition mechanism as the basis for selectivity. Such an inhibitory mechanism may be applicable to other homologous enzymes.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Binding Sites
-
Catalytic Domain
-
Crystallography, X-Ray
-
DNA / chemistry
-
DNA, Complementary / metabolism
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / chemistry*
-
Escherichia coli / metabolism
-
Humans
-
Inhibitory Concentration 50
-
Kinetics
-
Leucine / chemistry
-
Models, Chemical
-
Models, Molecular
-
Molecular Conformation
-
Mutagenesis
-
Mutagenesis, Site-Directed
-
Mutation
-
Protein Binding
-
Protein Conformation
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1
-
Protein Tyrosine Phosphatases / chemistry*
-
Recombinant Proteins / chemistry
-
Valine / chemistry
Substances
-
DNA, Complementary
-
Enzyme Inhibitors
-
Recombinant Proteins
-
DNA
-
PTPN1 protein, human
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1
-
Protein Tyrosine Phosphatases
-
Leucine
-
Valine